David Raben, Chief Medical Officer at Bicara Therapeutics Inc. (BCAX), sold 11,000 shares at $18.95 ($208K) on 2026-03-25, disclosed to the SEC on 2026-03-26.
Scheduled sale ($208k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.95 | 5,500 | $104K | 50.0% |
| 2 | $18.95 | 5,500 | $104K | 50.0% |
| Total | $18.95 avg | 11,000 | $208K | 100% |
| Filing → |
| BCAX | SELL | 2025-11-25 | $292K | — | Filing → |
| BCAX | SELL | 2025-10-10 | $406K | — | Filing → |